Clinical Trial Detail

NCT ID NCT02423863
Title In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

melanoma

skin cancer

head and neck squamous cell carcinoma

sarcoma

Therapies

Poly ICLC

Age Groups: adult

No variant requirements are available.